medigraphic.com
Colegio de Medicina Interna de México.

2024, Number 4

<< Back Next >>

Med Int Mex 2024; 40 (4)

Antibiotic resistance and mortality in Pseudomonas aeruginosa infection

Mesinas GM, Díaz RA, Minutti PA, López VCE

Language: Spanish
References: 32
Page: 249-257
PDF size: 224.86 Kb.


ABSTRACT

Objective: To determine antimicrobial susceptibility and mortality in patients with Pseudomonas aeruginosa infection.
Materials and Methods: An observational, transversal, descriptive and retrospective study was done to evaluate sensitivity pattern in Pseudomonas aeruginosa isolation; mortality on infected patients was also assessed.
Results: There were included 59 patients, the median age was 57 years (range 41 to 71 years), lung isolation was the most common in 26 cases; 48 cases of infection were hospital-acquired, 20 patients died; 32/59 patients received antibiotic treatment with activity against Pseudomonas and had a favorable outcome. Resistance to ceftazidime, amikacin, gentamicin, and ciprofloxacin was more common among those who died. Risk factors for mortality included SARS-CoV-2 infection, hospital-acquired, stay in intensive care unit, mechanical ventilation and treatment without coverage against Pseudomonas.
Conclusions: In Pseudomonas aeruginosa infection, receiving ineffective antimicrobial treatment is the most important risk factor associated to death. Antimicrobial resistance showed no impact on outcome.


REFERENCES

  1. Qin S, Xiao W, Zhou C, Pu Q, Deng X, Lan L, et al. Pseudomonasaeruginosa: Pathogenesis, virulence factors, antibioticresistance, interaction with host, technology advances andemerging therapeutics. Sig Transduct Target Ther 2022; 7(1). https://doi.org/10.1038/s41392-022-01056-1

  2. Bennett JE, Dolin R, Blaser MJ. 219 Pseudomonas aeruginosay otras especies de Pseudomonas. En: Enfermedadesinfecciosas: Principios y práctica: Mandell, Douglas y Bennet.9th ed. Barcelona: Elsevier España; 2021: 2518-30.

  3. Moradali MF, Ghods S, Rehm BH. Pseudomonas aeruginosalifestyle: A paradigm for adaptation, survival, and persistence.Front Cel Infect Microbiol 2017; 7. doi: 10.3389/fcimb.2017.00039

  4. Klockgether J, Tümmler B. Recent advances in understandingPseudomonas aeruginosa as a pathogen.F1000Research 2017; 6: 1261. doi: 10.12688/f1000research.10506.1

  5. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M,Monnet DL, et al. Discovery, research, and development ofnew antibiotics: The who priority list of antibiotic-resistantbacteria and tuberculosis. Lancet Infect Dis 2018;18 (3):318-27. doi: 10.1016/S1473-3099(17)30753-3

  6. Rasamiravaka T, Labtani Q, Duez P, El Jaziri M. The formationof biofilms by Pseudomonas aeruginosa: A reviewof the natural and synthetic compounds interfering withcontrol mechanisms. BioMed Res Int 2015; 2015: 1-17. doi:10.1155/2015/759348

  7. de Abreu PM, Farias PG, Paiva GS, Almeida AM, MoraisPV. Persistence of microbial communities includingPseudomonas aeruginosa in a hospital environment: Apotential health hazard. BMC Microbiology 2014; 14 (1).doi: 10.1186/1471-2180-14-118

  8. Voor in ‘t holt AF, Severin JA, Lesaffre EM, Vos MC. Asystematic review and meta-analyses show that carbapenemuse and medical devices are the leading risk factorsfor carbapenem-resistant Pseudomonas aeruginosa.Antimicrob Agents Chemother 2014; 58 (5): 2626-37. doi:10.1128/AAC.01758-13

  9. Arancibia F, Bauer TT, Ewig S, Mensa J, Gonzalez J, NiedermanMS, et al. Community-acquired pneumonia dueto gram-negative bacteria and pseudomonas aeruginosa.Arch Int Med 2002; 162 (16): 1849. doi: 10.1001/archinte.162.16.1849

  10. Pachori P, Gothalwal R, Gandhi P. Emergence of antibioticresistance Pseudomonas aeruginosa in intensive care unit;a critical review. Gen Dis 2019; 6 (2): 109-19. doi: 10.1016/j.gendis.2019.04.001

  11. Mesaros N, Nordmann P, Plésiat P, Roussel-Delvallez M,Van Eldere J, Glupczynski Y, et al. Pseudomonas aeruginosa:Resistance and therapeutic options at the turn of the NewMillennium. Clin Microbiol Infect 2007; 13 (6): 560-78. doi:10.1111/j.1469-0691.2007.01681.x

  12. Mesaros N, Nordmann P, Plésiat P, Roussel-Delvallez M,Van Eldere J, Glupczynski Y, et al. Pseudomonas aeruginosa:Resistance and therapeutic options at the turn of the NewMillennium. Clin Microbiol Infect 2007; 13 (6): 560-78. doi:10.1111/j.1469-0691.2007.01681.x

  13. Park S-Y, Park HJ, Moon SM, Park K-H, Chong YP, KimM-N, et al. Impact of adequate empirical combinationtherapy on mortality from bacteremic Pseudomonasaeruginosa pneumonia. BMC Infect Dis 2012; 12 (1). doi:10.1186/1471-2334-12-308

  14. Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Robles AguilarG, Gray A, et al. Global burden of bacterial antimicrobialresistance in 2019: A systematic analysis. Lancet 2022; 399(10325): 629-55. doi: 10.1016/S0140-6736(21)02724-0

  15. Basak S, Singh P, Rajurkar M. Multidrug resistant and extensivelydrug resistant bacteria: A study. J Pathog 2016;2016: 4065603. doi: 10.1155/2016/4065603

  16. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van DuinD, Clancy CJ. Infectious Diseases Society of America Antimicrobial-Resistant Treatment Guidance: Gram-NegativeBacterial Infections. Infectious Diseases Society of America2023; Version 3.0.

  17. Panorama epidemiológico de las infecciones asociadas a laatención de la salud (IAAS), México, agosto 2022.

  18. Garza-González E, Franco-Cendejas R, Morfín-Otero R,Echaniz-Aviles G, Rojas-Larios F, Bocanegra-Ibarias P, et al.The evolution of antimicrobial resistance in Mexico duringthe last decade: Results from the INVIFAR Group. MicrobDrug Resistance 2020; 26 (11): 1372-82. doi:10.1089/mdr.2019.0354

  19. Garza-González E, Morfín-Otero R, Mendoza-Olazarán S,Bocanegra-Ibarias P, Flores-Treviño S, Rodríguez-NoriegaE, et al. A snapshot of antimicrobial resistance in Mexico.results from 47 centers from 20 states during a six-monthperiod. PLoS One 2019; 14 (3). doi: 10.1371/journal.pone.0209865

  20. Blair JM, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJ.Molecular mechanisms of antibiotic resistance. Nature RevMicrobiol 2014; 13 (1): 42-51. doi: 10.1038/nrmicro3380.

  21. Morata L, Cobos-Trigueros N, Martínez JA, Soriano Á, AlmelaM, Marco F, et al. Influence of multidrug resistanceand appropriate empirical therapy on the 30-day mortalityrate of Pseudomonas aeruginosa bacteremia. AntimicrobAgents Chemother 2012; 56 (9): 4833-7. doi: 10.1128/AAC.00750-12

  22. Chamot E, Boffi El Amari E, Rohner P, Van Delden C.Effectiveness of combination antimicrobial therapyfor Pseudomonas aeruginosa bacteremia. AntimicrobAgents Chemother 2003; 47 (9): 2756-64. doi: 10.1128/AAC.47.9.2756-2764.2003

  23. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S,et al. Duration of hypotension before initiation of effectiveantimicrobial therapy is the critical determinant of survivalin human septic shock. Crit Care Med 2006; 34 (6): 1589-96.doi: 10.1097/01.CCM.0000217961.75225.E9

  24. Dantas RC, Ferreira ML, Gontijo-Filho PP, Ribas RM.Pseudomonas aeruginosa bacteraemia: Independent riskfactors for mortality and impact of resistance on outcome.J Med Microbiol 2014; 63 (12): 1679-87. doi: 10.1099/jmm.0.073262-0

  25. Jeong SJ, Yoon SS, Bae IK, Jeong SH, Kim JM, Lee K. Riskfactors for mortality in patients with bloodstream infectionscaused by carbapenem-resistant Pseudomonas aeruginosa:Clinical impact of bacterial virulence and strains onoutcome. Diagnost Microbiol Infect Dis 2014; 80 (2): 130-5.doi: 10.1016/j.diagmicrobio.2014.07.003

  26. Kumar VA, Khan S. Defining multidrug resistance in gramnegativebacilli. Indian J Med Res 2015; 141 (4): 491. doi:10.4103/0971-5916.159318

  27. Bagge N, Hentzer M, Andersen JB, Ciofu O, Givskov M,Høiby N. Dynamics and spatial distribution of β-lactamaseexpression in pseudomonas aeruginosa biofilms. AntimicrobAgents Chemother 2004; 48 (4): 1168-74. doi:10.1128/AAC.48.4.1168-1174.2004

  28. Hernández A, Yagüe G, García Vázquez E, Simón M, MorenoParrado L, Contreras M, et al. Nosocomial infections causedby multiresistant Pseudomonas aeruginosa (carbapenemsincluded): predictive and prognostic factors. A prospectivestudy (2016-2017). Rev Esp Quimioterapia 2012; 31 (2).

  29. Tumbarello M, De Pascale G, Trecarichi EM, Spanu T,Antonicelli F, Maviglia R, et al. Clinical outcomes of Pseudomonasaeruginosa pneumonia in intensive care unitpatients. Int Care Med 2013; 39 (4): 682-92. doi: 10.1007/s00134-013-2828-9

  30. Kim YJ, Jun YH, Kim YR, Park KG, Park YJ, Kang JY, et al.Risk factors for mortality in patients with Pseudomonasaeruginosa bacteremia; retrospective study of impact ofcombination antimicrobial therapy. BMC Infect Dis 2014;14 (1). doi: 10.1186/1471-2334-14-161

  31. Suárez C, Peña C, Gavaldà L, Tubau F, Manzur A, DominguezMA, et al. Influence of carbapenem resistance onmortality and the dynamics of mortality in Pseudomonasaeruginosa bloodstream infection. Int J Infect Dis 2010; 14.doi: 10.1016/j.ijid.2009.11.019

  32. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, CarmeliY. Multidrug-resistant Pseudomonas aeruginosa: Riskfactors and clinical impact. Antimicrob Agents Chemother2006; 50 (1): 43-8. doi: 10.1128/AAC.50.1.43-48.2006




2020     |     www.medigraphic.com